Accéder au contenu
Merck

Cardiac-peripheral transvenous gradients of microRNA expression in systolic heart failure patients.

ESC heart failure (2020-04-08)
Inbar Ben-Zvi, Natalia Volinsky, Liza Grosman-Rimon, Izhak Haviv, Guy Rozen, Nizar Andria, Nofar Asulin, Nufar Margalit, Ibrahim Marai, Offer Amir
RÉSUMÉ

The aims of the study are to assess the levels of coronary sinus (CS) miRNAs of systolic heart failure (HF) patients in samples obtained during cardiac resynchronization therapy (CRT) device implantation and compare them to the peripheral systemic venous miRNA expression. The cardiac specific miRNA levels were assessed in 60 patients, 39 HF patients with reduced ejection fraction and 21 control patients. The levels of four cardiac specified miRNAs (miR-21-5p, miR-92b-3p, miR-125b-5p, and miR-133a-3p) were compared between the peripheral samples of HF and controls and between peripheral venous in CS in the HF groups. Compared with controls, HF patients had higher peripheral serum venous levels of miR-125b-5p and miR-133-3p. In the HF group, the levels of expression were higher for miR-125b-5p and lower for miR-92, and miR-21-5p in the CS, compared with the peripheral venous circulation. The differences in miRNA expressions in CS compared with those in the periphery suggest that changes that may occur at the levels of the myocardial tissue in HF may be more relevant to our understanding of the biological linkage between miRNA expression and HF, than the traditional analysis of systemic serum miRNA expression.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Tampon Tris-EDTA, BioUltra, for molecular biology, pH 8.0